Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Chelators as antineuroblastomas agents

Cosimo Walte D'Acunto, Helena Gbelcová, Robert Kaplánek, Monika Pospíšilová, Martin Havlík, Tomáš Ruml

. 2023 ; 72 (Suppl. 3) : S277-S286. [pub] 2023Oct27

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc23022220

Neuroblastoma represents 8-10 % of all malignant tumors in childhood and is responsible for 15 % of cancer deaths in the pediatric population. Aggressive neuroblastomas are often resistant to chemotherapy. Canonically, neuroblastomas can be classified according to the MYCN (N-myc proto-oncogene protein) gene amplification, a common marker of tumor aggressiveness and poor prognosis. It has been found that certain compounds with chelating properties may show anticancer activity, but there is little evidence for the effect of chelators on neuroblastoma. The effect of new chelators characterized by the same functional group, designated as HLZ (1-hydrazino phthalazine), on proliferation (WST-1 and methylene blue assay), cell cycle (flow cytometry), apoptosis (proliferation assay after use of specific pharmacological inhibitors and western blot analysis) and ROS production (fluorometric assay based on dichlorofluorescein diacetate metabolism) was studied in three neuroblastoma cell lines with different levels of MYCN amplification. The molecules were effective only on MYCN-non-amplified cells in which they arrested the cell cycle in the G0/G1 phase. We investigated the mechanism of action and identified the activation of cell signaling that involves protein kinase C.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23022220
003      
CZ-PrNML
005      
20250402155343.0
007      
ta
008      
240104s2023 xr ad f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.935184 $2 doi
035    __
$a (PubMed)37888971
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a D'Acunto, Cosimo Walte $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague 6, Czech Republic $u Analytical Development & Innovation, Merck Serono S.p.A., Rome, Italy
245    10
$a Chelators as antineuroblastomas agents / $c Cosimo Walte D'Acunto, Helena Gbelcová, Robert Kaplánek, Monika Pospíšilová, Martin Havlík, Tomáš Ruml
520    9_
$a Neuroblastoma represents 8-10 % of all malignant tumors in childhood and is responsible for 15 % of cancer deaths in the pediatric population. Aggressive neuroblastomas are often resistant to chemotherapy. Canonically, neuroblastomas can be classified according to the MYCN (N-myc proto-oncogene protein) gene amplification, a common marker of tumor aggressiveness and poor prognosis. It has been found that certain compounds with chelating properties may show anticancer activity, but there is little evidence for the effect of chelators on neuroblastoma. The effect of new chelators characterized by the same functional group, designated as HLZ (1-hydrazino phthalazine), on proliferation (WST-1 and methylene blue assay), cell cycle (flow cytometry), apoptosis (proliferation assay after use of specific pharmacological inhibitors and western blot analysis) and ROS production (fluorometric assay based on dichlorofluorescein diacetate metabolism) was studied in three neuroblastoma cell lines with different levels of MYCN amplification. The molecules were effective only on MYCN-non-amplified cells in which they arrested the cell cycle in the G0/G1 phase. We investigated the mechanism of action and identified the activation of cell signaling that involves protein kinase C.
650    _2
$a dítě $7 D002648
650    _2
$a lidé $7 D006801
650    _2
$a protoonkogen n-myc $x genetika $x metabolismus $x terapeutické užití $7 D000071447
650    12
$a onkogenní proteiny $x genetika $x metabolismus $x farmakologie $7 D015513
650    _2
$a jaderné proteiny $x genetika $7 D009687
650    _2
$a chelátory $x farmakologie $x terapeutické užití $7 D002614
650    12
$a neuroblastom $x farmakoterapie $7 D009447
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a apoptóza $7 D017209
650    _2
$a proliferace buněk $7 D049109
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gbelcová, Helena, $d 1982- $7 xx0257254 $u Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University in Bratislava, Bratislava, Slovak Republic
700    1_
$a Kaplánek, Robert $7 _AN061422 $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague 6, Czech Republic $u First Faculty of Medicine-BIOCEV, Charles University, Prague, Czech Republic
700    1_
$a Pospíšilová, Monika, $d 1977- $7 xx0076299 $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague 6, Czech Republic
700    1_
$a Havlík, Martin $7 _AN121912 $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague 6, Czech Republic $u First Faculty of Medicine-BIOCEV, Charles University, Prague, Czech Republic
700    1_
$a Ruml, Tomáš, $d 1954- $7 nlk20030128618 $u Department of Biochemistry and Microbiology, University of Chemistry and Technology, Prague 6, Czech Republic
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 72, Suppl. 3 (2023), s. S277-S286
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37888971 $y Pubmed
910    __
$a ABA008 $b A 4120 $c 266 $y p $z 0
990    __
$a 20240104 $b ABA008
991    __
$a 20250402155339 $b ABA008
999    __
$a ok $b bmc $g 2294506 $s 1208664
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 72 $c Suppl. 3 $d S277-S286 $e 2023Oct27 $i 1802-9973 $m Physiological research $n Physiol Res $x MED00003824
LZP    __
$b NLK124 $a Pubmed-20240104

Find record

Citation metrics

Archiving options